TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Why is an elderly prognostic index required for patients with DLBCL?

Featured:

Michele SpinaMichele Spina

Dec 12, 2019


During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Michele Spina, National Cancer Institute, Aviano, IT. We asked: Why is an elderly prognostic index required for patients with diffuse large B-cell lymphoma, and how can it be used in clinical practice?

Michele Spina discusses the multicenter study behind the development of a novel geriatric assessment tool, the elderly prognostic index. This tool can help address the challenges of managing elderly patients with DLBCL, including the undertreatment, or toxicity associated with unnecessary treatment and polypharmacy. Geriatric assessment can accurately stratify patients based on the prognosis and help to decide on the treatment regimen.

Why is an elderly prognostic index required for patients with DLBCL?